Replicel Life Sciences Inc V.RP

Alternate Symbol(s): REPCF

Technology Scientific & Technical Instruments

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.

TSXV:RP - Post by User

Replicel Life Sciences Inc > OFFICIAL RELEASE OF SHISEIDOS HAIR REGENERATION

<< Previous

Bullboard Posts

Next >>

Comment by MetzGERon Jun 29, 2024 8:07am

64 Views

Post# 36111911

RE:OFFICIAL RELEASE OF SHISEIDOS HAIR REGENERATION

We should start legal proceedings immediately. @rpinvestor what steps do you recommend?

This is the company of all of us. We don't let them stole. If there is Insider Dealing the Court will give Main actors of this expropriation attempt heavy penalty.

<< Previous

Bullboard Posts

Next >>

AI companies to invest in